Alzheimer’s disease (memory loss is drastic) is the most terrifying threat of people over the age of 50 years. Memory alive for decades gone so fast could not even recognize the people closest.
Various efforts have been made to treat diseases of the brain function of this decline, but there is a powerful yet healed. Because of this disease difficult to cure, researchers are now focusing on prevention efforts.
Researchers from the Massachusetts Institute of Technology to create a drink that can Souvenaid become a drug for Alzheimer’s. The drink contains 3 main components that can sustain brain synapses, namely uridine, choline, and omega-3 (DHA).
One of the cirri of Alzheimer’s disease is the loss of synapses that connect a network or system that links between nerve cells or with muscles. Reduced synaptic connections made between the brain’s ability to remember the poor and the place of language disorders that eventually lead to Alzheimer’s disease.
Researchers try to drink 225 mild Alzheimer’s patients and found that the product helps patients in memory tests. Souvenaid products planned to be commercialized next year by the manufacturer Nutricia under perudahaan giant Danone.
Meanwhile, Yian Gu, a neurologist doctorate from Columbia University Medical Center says, Alzheimer’s disease related to diet.
“It would be better if this study compared with the use of multivitamins and fish oil consumed a lot of people to improve memory so that people can know which is more effective and not,” said Gu.
In addition to anti-forgotten memories beverages, researchers also suggested that someone who has Alzheimer’s symptoms immediately detect the brain with an MRI scanner to determine the structure of the brain and the memory that stores hippopocampus. The level of diffusion of water into brain cells also proved to be a factor affecting the ability to recall and brain structures.
The study, published in the Journal of the American Medical Association also suggested that someone check his brain with an MRI device when entering the age of 50 years to determine whether or not the possibility that Alzheimer’s disease can be treated early
